Role of the Epstein-Barr virus-encoded latent membrane protein-1 LMP1, in the pathogenesis of nasopharyngeal carcinoma

Future Oncology

Volumn 5, Issue 6, 2009, Pages 811-825

  Morris, Mhairi A ^a   Dawson, Christopher W ^a   Young, Lawrence S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

EBV; Epstein Barr virus; Latent membrane protein 1; LMP1; Nasopharyngeal carcinoma; NPC

Indexed keywords

CD40 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; SYNAPTOPHYSIN;

APOPTOSIS; CANCER INVASION; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; EPSTEIN BARR VIRUS; EXTRACELLULAR MATRIX; HUMAN; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

CARCINOMA; CELL PROLIFERATION; HUMANS; NASOPHARYNGEAL NEOPLASMS; TNF RECEPTOR-ASSOCIATED FACTOR 2; VIRAL MATRIX PROTEINS;

EID: 70349210826     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.53     Document Type: Review

References (128)

1. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757-768 (2004).
2. Chan AS, To KF, Lo KW et al.: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 60(19), 5365-5370 (2000).
3. Chan AS, To KF, Lo KW et al.: Frequent chromosome 9p losses in histologically hormal nasopharyngeal epithelia from southern Chinese. Int. J. Cancer 102(3), 300-303 (2002).
4. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N: Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333(11), 693-698 (1995).
5. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43(3 Part 2), 831-840 (1985).
6. Baichwal VR, Sugden B: Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2(5), 461-467 (1988).
7. Kaye KM, Izumi KM, Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90(19), 9150-9154 (1993).
8. Fahraeu R, Rymo L, Rhim JS, Klein G: Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-8arr virus. Nature 345(6274), 447-449 (1990).
9. Dawson CW, Rickinson AB, Young LS: Epstein-Barr virus latent membrane protein inhibits human epithelia] cell differentiation. Nature 344, (6268), 777-780 (1990).
10. Stevenson D, Charalambous C, Wilson JB: Epstein-Barr virus latent membrane protein 1 (CAO) upregulates VEGF and TGF α concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res. -65(19), 8826-8835 (2005).
11. Brooks L, Yao QY, Rickinson AB, Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66(5:2689-2697 (1992).
12. Young LS, Dawson CW, Clark D et al.: Epstein--Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69(Part5), 1051-1065 (1988).
13. Khabir A, Karray H, Rodriguez S et al.: EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol. J. 2, 39 (2005).
14. Hu LF, Minarovits J, Cao SL et al.: Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5′-flanking region. J. Virol. 65(3), 1558-1567 (1991).
15. Hu L, Troyanovsky B, Zhang X, Trivedi P, Ernberg I, Klein G: Differences in the immunogenicity of latent membrane protein 1 (IMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma. Cancer Res. 60(19), 5589-5593 (2000).
16. Trivedi P, Hu LF, Chen F et al.: Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur. J. Cancer 30A(1), 84-88 (1994).
17. Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF: Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res. 24(4), 2309-2318 (2004).
18. Niedobitek G, Meru N, Delecluse HJ: Epstein-Barr virus infection and human malignancies. Int. J. Exp. Pathol. 82(3), 149-170 (2001).
19. Hammerschmidt W, Sugden B, Baichwal VR: The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J. Virol. 63(6), 2469-2475 (1989).
20. Lu JJ, Chen JY, Hsu TY, Yu WC, Su IJ, Yang CS: Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 77(Part 8), 1883-1892 (1996).
21. Liu Y, Wang X, Lo AK, Wong YC, Cheung AL, Tsao SW: Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopnaryngeal carcinoma cells. J. Med. Virol. 66(1), 63-69 (2002).
22. Du C, Wen B, Li D et al.: Downregulation of Epstein-Barr virus encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cells. Tumori 92(2), 140-148 (2006).
23. Gires O, Zimber-Strobl U, Gonnella R et al.: Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16(20), 6131-6140 (1997).
24. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80(3), 389-399 (1995).
25. Eliopoulos AG, Young LS: LMP1 structure and signal transduction. Semin. Cancer Biol. 11(6), 435-444 (2001).
26. Uchida J, Yasui T, Takaoka-Shichijo Y et al.: Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286(5438), 300-303 (1999).
27. Aviel S, Winberg G, Massucci M, Ciechanover A: Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J. Biol. Chem. 275(31), 23491-23499 (2000).
28. Lo AK, To KF, Lo KW et al.: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. USA 104(41), 16164-16169 (2007).
29. Kaykas A, Worringer K, Sugden B: LMP-1's transmembrane domains encode multiple functions required for LMP-1's efficient signaling. J. Virol. 76(22), 11551-11560 (2002).
30. Puls A, Eliopoulos AG, Nobes CD, Bridges T, Young LS, Hall A. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(α) and IL-4 and by the Epstein-Barr virus transforming protein LMP1. J. Cell Sci. 112(Part 17), 2983-2992 (1999).
31. Eliopoulos AG, Stack M, Dawson CW et al.: Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF rcceptor-associated factors. Oncogene 14(24), 2899-2916 (1997).
32. Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor- associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. USA 94(23), 12592-12597 (1997).
33. Mainou BA, Everly DN Jr, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 24(46), 6917-6924 (2005).
34. Sandberg M, Hammerschmidt W, Sugden B: Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J. Virol. 71(6), 4649-4656 (1997).
35. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS: Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73(2), 1023-1035 (1999).
36. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS: Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulatcs interleukin-6 and interleukin-8 production. J. Biol. Chem. 274(23), 16085-16096 (1999).
37. Chung PJ, Chang YS, Liang CL, Meng CL: Negative regulation of Epstein-Barr virus latent membrane protein 1-mediated functions by the bone morphogenetic protein receptor IA-binding protein, BRAM1. J. Biol. Chem. 277(42), 39850-39857 (2002).
38. Li HP, Chang YS: Epstein-Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci. 10(5), 490-504 (2003).
39. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS: Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 278(6), 3694-3704 (2003).
40. Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS: Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J. Virol. 82(7), 3654-3664 (2008).
41. Gires O, Kohlhuber F, Kilger E et al.: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18(11), 3064-3073 (1999).
42. Higuchi M, Kieff E, Izumi KM: The Epstein-Barr virus latent membrane protein 1 putative Janus-kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J. Virol. 76(1), 455-459 (2002).
43. Lo KW, To KF, Huang DP. Focus on- nasopharyngeal carcinoma. Cancer Cell 5(5), 423-428 (2004).
44. Tan Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert. Rev. Mol. Med. 9(12), 1-24 (2007).
45. Soussi T, Ishioka C, Claustres M, Béroud C: Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 6(1), 83-90 (2006).
46. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ: High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19(30), 3439-3444 (2000).
47. Chu WK, Lee KC, Chow SE, Chen JK: Dual regulation of the ΔNp63 transcriptional activity by ΔNp63 in human nasopharyngeal carcinoma cell. Biocbem. Biophys. Res. Commun. 342(4), 1356-1360 (2006).
48. Guo C, Pan ZG, Li DJ et al.: The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J. Transl. Med. 4, 23 (2006).
49. Lo KW, Mok CH, Huang DP et al.: p53 mutation in human nasopharyngeal carcinomas. Anticancer Res. 12(6B), 1957-1963 (1992).
50. Spruck CH 3rd, Tsai YC, Huang DP et al.: Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res. 52(17), 4787-4790 (1992).
51. Chang KP, Hao SP, Lin SY et al.: A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy. Laryngoscope 112(11), 2015-2019 (2002).
52. Fries KL, Miller WE, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 70(12), 8653-8659 (1996).
53. Li L, Guo L, Tao Y et al.: Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett. 255(2), 219-231 (2007).
54. Wu HC, Lu TY, Lee JJ et al.: MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab. Invest. 84(12), 1547-1556 (2004).
55. Morris MA, Dawson CW, Wei W et al.: Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J. Gen. Virol. 89(Part II), 2806-2820 (2008).
56. Sheu LF, Chen A, Lee HS, Hsu HY, Yu DS: Cooperative interactions among p53, bcl-2 and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol Int. 54(7), 475-485 (2004).
57. Man C, Rosa J, Lee LT et al.: Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells. Oncogene 26(21), 3069-3080 (2007).
58. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25(3), 315-319 (2000).
59. Macdiarmid J, Stevenson D, Campbell DH, Wilson JB: The latent membrane protein 1 of Epstein-Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo. Carcinogenesis 24(7), 1209-1218 (2003).
60. Zheng H, Li LL, Hu DS, Deng XY, Cao Y: Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell. Mol. Immunol. 4(3), 185-196 (2007).
61. Everly DN Jr, Mainou BA, Raab-Traub N: The ID proteins contribute to the growth of rodent fibroblasts during LMP1-mediated transformation. Virology 376(2), 258-269 (2008).
62. Cheung ST, Huang DP, Hui AB et al.: Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83(1), 121-126 (1999).
63. Mei YP, Zhou JM, Wang Y et al.: Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in FBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6(11), 1379-1385 (2007).
64. Li XP, Li G, Peng Y, Kung HF, Lin MC: Suppression of Epstein-Barr virus-encoded latent membrane protein 1 by RNA interference inhibits the metastatic potential of nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 315(1), 212-218 (2004).
65. Jin X, Song X, Li L pet al.: Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol. Carcinog. 46(11), 901-911 (2007).
66. Ai MD, Li LL, Zhao XR, Wu Y, Gong JP, Cao Y: Regulation of survivin and CDK4 by Epstein-Barr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cell lines. Cell Res. 15(10), 777-784 (2005).
67. Seo SY, Kim EO, Jang KL: Epstein-Barr virus latent membrane protein 1 suppresses the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-β2 expression via DNA methylation. Cancer Lett. 270(1), 66-76 (2008).
68. Tao Y, Song X, Deng X et al.: Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res. 303(2), 240-251 (2005).
69. Liu B, Chen XY: [Effect of EB virus latent membrane protein 1 on mitosis control of nasopharyngeal carcinoma cell line CNE1]. Ai Zheng 23(5), 512-516 (2004).
70. Li G, Li XP, Peng Y, Liu X, Li XH: Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBV-positive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Rao 24(3), 241-246 (2004).
71. Lin X, Liu S, Luo et al.: EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int. J. Cancer 124(5), 1020-1027 (2009).
72. Ding L, Li LL, Yang et al.: Epstein-Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-κB p65 in human nasopharyngeal carcinoma cells. Int. J. Biochem. Cell Biol. 37(9), 1881-1889 (2005).
73. Siegler G, Meyer B, Dawson C et al.: Expression of tumor necrosis factor receptor- associated factor 1 in nasopharyngeal carcinoma: possible upregulation by Epstein-Barr virus latent membrane protein 1. Int. J. Cancer 112(2), 265-272 (2004).
74. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML: Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 274(33), 23013-23019 (1999).
75. Wheelock MJ, Johnson KR: Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol. 19, 207-235 (2003).
76. Fahraeus R, Chen W, Trivedi P, Klein G, Obrink B: Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfectcd human epithelial and murine adenocarcinoma cells. Int. J. Cancer 52(5), 934-838 (1992).
77. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogen product, latent membrane protein 1, induce the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc. Natl. Acad. Sci. USA 99(15), 10084-10089 (2002).
78. Horikawa T, Yang J, Kando, S et al.: Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res. 67(5), 1970-1978 (2007).
79. Tsai CL, Li HP, Lu YJ et al.: Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 66(24), 11668-11676 (2006).
80. Krishna SM, Kattoor J, Balaram P: Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas. Cancer Biomark. 1(6), 271-277 (2005).
81. Zhang ZW, He ZM, Zhou M, Ding W, Yu YH, Chen ZC: [Mechanism of migration in CNE2 cells promoted by EBV-LMP1]. Zhong Nan Da Xue Xue Boo Yi Xue Ban 31(4), 470-474 (2006).
82. Shair KH, Schnegg CI, Raab-Traub N: EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res. 68(17), 6997-7005 (2008).
83. Gendler SJ: MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 6(3), 339-353 (2001).
84. Kim YS, Gum J Jr, Brockhausen I: Mucin glycoproteins in neoplasia. Glycoconj. J. 13(5), 693-707 (1996).
85. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M: Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod. Pathol. 16(5), 403-410 (2003).
86. Ringel J, Lohr M: The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol. Cancer 2, 9 (2003).
87. Taylor-Papadimitriou J, Burchell JM, Plunkett T et al.: MUC and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 7(2), 209-221 (2002).
88. Baldus SE, Engelmann K, Hanisch FG: MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci. 41(2), 189-231 (2004).
89. Kondo S, Yoshizaki T, Wakisaka N et al.: MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the - cell-matrix interaction and cellular invasiveness via STAT signaling. J. Virol. 81(4), 1554-1562 (2007).
90. Lo AK, Liu Y, Wang XH et al.: Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. Lab. Invest. 83(5), 697-709 (2003).
91. Liu LT, Peng JP, Chang HC, Hung WC: RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 22(51), 8263-8270 (2003).
92. Kim KR, Yoshizaki T, Miyamori H et al.: Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 19(14), 1764-1771 (2000).
93. Zeng L, Liu YP, Wang H et al.: [EB virus encoded latent membrane protein 1 mediated expression of transcription factor Ets-1 in nasopharyngeal carcinoma cells]. Zhonghua Zhong Liu Za Zhi 26(8), 454-457 (2004).
94. Kwok Fung Lo A, Liu Y, Wang X et al.: Identification of downstream target genes of latent membrane protein 1 in nasopharyngeal carcinoma cells by suppression subtractive hybridization. Biochim. Biophys. Acta 1520(2), 131-140 (2001).
95. Yang J, Mani SA, Donaher JL et al.: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7), 927-939 (2004).
96. Shen ZH, Chen XY, Chen J: [Impact of up-regulating Ezrin expression by Epstein- Barr virus latent membrane protein 1 on metastasis ability of nasopharyngeal carcinoma cells]. Ai Zheng 27(2), 165-169 (2008).
97. Liu QY, Han AJ, You SY et al.: [Correlation of Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) to fascin and phosphorylated Stat3 in nasopharyngeal carcinoma]. Ai Zheng 27(10), 1070-1076 (2008).
98. Horikawa T, Sheen TS, Takeshita H, Sam H, Furukawa M, Yoshizaki T: Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol. 159(1), 27-33 (2001).
99. Lukashev ME, Werb Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8(11), 437-441 (1998).
100. Yoshizaki T: Promotion of metastasis in nasopharyngeal carcinoma by Epstein-Barr virus latent membrane protein-1. Histol. Histopathol. 17(3), 845-850 (2002).
101. Gou XM, Chen Y, Chen XY, Arrand JR: [Effects of Epstein-Barr virus latent membrane protein 1(EBV-LMP1) on related factors of metastasis of nasopharyngeal carcinoma cell line CNE1]. Ai Zheng 22(5), 481-485 (2003).
102. Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA 95(7), 3621-3626 (1998).
103. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89(4), 715-723 (2000).
104. Kondo S, Wakisaka N, Schell MJ et al.: Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int. J. Cancer 115(3), 368-376 (2005).
105. Zeng L, Liu YP, Tan YG, Ai MD, Zhao XR, Cao Y: [Cross-talk between c-Jun/ Ets1 involved in EB virus-encoded latent membrane protein 1 regulates expression of matrix metalloproteinase-9 in nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi 27(4), 204-208 (2005).
106. Bergers G, Brekken R, McMahon G et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2(10), 737-744 (2000).
107. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS: Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 60(9), 2555-2561 (2000).
108. Lee DC, Chua DT, Wei WI, Sham JS, Lau AS: Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed. Pharmacother. 61(9), 520-526 (2007).
109. Chang SH, Chang HC, Hung WC: Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein-Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells. Oral Oncol. 41(9), 891-897 (2008).
110. Kondo S, Seo SY, Yoshizaki T et al.: EBV latent membrane protein 1 up-regulates hypoxia- inducible factor 1α through Siahl-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 66(20), 9870-9877 (2006).
111. Murono S, Inoue H, Tanabe T et al.: Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA 98(12), 6905-6910 (2001).
112. Wakisaka N, Kondo, S, Yoshizaki T, Murono S, Furukawa M, Pagano JS: Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 α. Mol. Cell. Biol. 24(12), 5223-5234 (2004).
113. Yoshizaki T, Horikawa T, Qing-Chun R et al.: Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenests in nasopharyngeal carcinoma. Clin. Cancer Res. 7(7), 1946-1951 (2001).
114. Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T: Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-κ B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 114(5), 855-859 (2004).
115. Tsuji A, Wakisaka N, Kondo S, Murono S, Furukawa M, Yoshizaki T: Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin. Cancer Res. 14(17), 5368-5375 (2008).
116. Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N: Potential selection of LMP1 variants in nasopharyngeal carcinoma. J. Virol. 78(2), 868-881 (2004).
117. Burrows JM et al.: Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J. Virol. 78(13), 7131-7137 (2004).
118. Chen ML, Tsai CN, Liang CL et al.: Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7(11), 2131-2140 (1992).
119. Hu LF, Zabarovsky ER, Chen F et al.: Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 72(Part 10), 2399-2409 (1991).
120. Li SN, Chang YS, Liu ST: Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12(10), 2129-2135 (1996).
121. Blake SM, Eliopoulos AG, Dawson CW, Young LS: The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 282(2), 278-287 (2001).
122. Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS: Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology 272(1), 294-217 (2000).
123. Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, Rowe M: Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J. Virol. 75(19), 9129-9141 (2001).
124. Nitta T, Chiba A, Yamamoto N, Yamaoka S: Lack of cytotoxic property in a variant of Epstrin-Barr virus latent membrane protein-1 isolated from nasopharyngeal carcinoma. Cell Signal. 16(9), 1071-1081 (2004).
125. Huang H, Huang PC: [Effects of two LMP1 variants on resistance of CNE1 cell strain to TGF-β1]. Ai Zheng 22(12), 1254-1259 (2003).
126. Hadhri-Guiga B, Chiba A, Yamamoto N, Yamaoka S: Various 30 and 69 bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res. 115(1), 24-30 (2006).
127. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS: Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88(9), 3491-3501 (1996).
128. Chang KP, Hao SP, Lin SY et al.: The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 116(4), 541-546 (2006).